News Center

位置：

Honors Announcement

Group News

Media Reports

Grand Launch Conference Held for Shijiazhuang Sihua Pharmaceutical Group’s 2022 Policies and Objectives

Category:

Group News

发布时间：2022-01-20

【概要描述】 On December 30, 2021, Shijiazhuang Sihua Pharmaceutical Group held a grand launch conference for its 2022 strategic objectives and targets. Qu Jiguang, Chairman of the Board of Directors, joined mid-level and senior managers from all subsidiaries to pool their wisdom and efforts in charting a new blueprint for the group’s high-quality development. The meeting was chaired by Shi Jianhui, Secretary of the Party Committee and Executive President of the Group.

Grand Launch Conference Held for Shijiazhuang Sihua Pharmaceutical Group’s 2022 Policies and Objectives

Continuing to forge ahead and usher in a new era, we will row vigorously and strive to write a new chapter. On December 30, 2021, Shijiazhuang Sihua Pharmaceutical Group held a grand press conference to unveil its 2022 strategic objectives. Qu Jiguang, Chairman of the Board, joined mid- and senior-level managers from all subsidiaries in a unified effort to map out a new blueprint for the group’s high-quality development. The meeting was chaired by Shi Jianhui, Secretary of the Party Committee and Executive President of the Group.

At the meeting, Group President Wu Hengyao delivered a work report on the formulation of the 2022 strategic objectives, systematically reviewing the Group’s production and business operations in 2021 and providing a detailed explanation of the process for developing the 2022 strategic objectives.

The heads of the Pharmaceutical Business Unit, Active Pharmaceutical Ingredient Business Unit, Centralized Procurement Center, R&D Center, Strategic Development Center, Manufacturing Center, and other departments, as well as the subsidiaries Jiangsu Bosheng Medical New Materials, Guangxiang Pharmaceutical, and Guolong Pharmaceutical, each delivered detailed reports on the achievement of the 2021 strategic objectives, the 2022 task targets and specific implementation measures, innovative initiatives, and project timelines. Group leaders Qu Jiguang, Su Xuejun, Wu Hengyao, and others provided comments and guidance.

Following the presentation of strategic objectives by the various centers, business units, and subsidiaries, Qu Jiguang, Chairman of the Group’s Board of Directors, delivered a significant address to the assembly. He noted that in 2021, under the united and collaborative efforts of the entire Group, we seized opportunities and effectively navigated the increasingly intense competition in the pharmaceutical market amid the new normal of the pandemic, as well as numerous other challenges arising from adjustments to industrial policies, reductions in drug prices, and rising costs of energy and raw and auxiliary materials. As a result, we achieved new advances, made fresh progress, and attained notable results across multiple fronts—including R&D innovation, quality assurance, market development, cost reduction, and project construction—and our key financial indicators reached new heights.

In light of the current situation, Chairman Qu Jiguang emphasized that 2022 is a pivotal year for the Group in achieving the strategic objectives set forth in the 14th Five-Year Plan, as well as a decisive year for advancing the IPO process of the pharmaceutical packaging materials and active pharmaceutical ingredient business segments. Achieving the Group’s policy objectives and mission for next year will be a formidable task; it is imperative to fully recognize existing shortcomings in mindset, work style, professional competence, and management practices. We must strike a balance between stability and speed, focusing our efforts on strengthening R&D and market development as the two key engines driving the Group’s high-quality growth. By maintaining steadfast resolve, consolidating our achievements, and leveraging favorable momentum, we will ensure the comprehensive and effective implementation of all annual tasks and targets.

To ensure the successful implementation of the 2022 production and business objectives, Chairman Qu Jiguang has outlined four key priorities: First, launch a targeted initiative to enhance research and development quality and efficiency by focusing on the most critical and urgent product categories driven by market demand, strengthening R&D efforts on pioneering new products, accelerating the regulatory approval process for pipeline candidates, shifting generic drug development from a quantity-driven to a quality-driven approach, and transitioning innovative drugs, active pharmaceutical ingredients, and pharmaceutical packaging materials from homogenization toward distinctive, differentiated offerings. Second, initiate a campaign to elevate technological and quality standards by streamlining technology transfer and technical support processes, bolstering the capabilities of the technical workforce, bridging the gap between R&D outcomes and market needs, and enhancing the supply and market penetration of new products. Third, undertake a decisive push to achieve breakthroughs in marketing by dismantling entrenched, rigid mindsets and making necessary adjustments at the conceptual, managerial, and organizational levels, deploying flexible, diversified, and robust measures to drive procurement-based centralized purchasing, clinical development, and expansion into all end-user markets. Fourth, launch an initiative to elevate management practices by reinforcing the central role of financial management in providing overarching strategic guidance and by improving performance across quality, environmental protection, safety, cost control, project development, and human resource management. As key pillars for the Group’s comprehensive operational breakthrough next year, Guangxiang Pharmaceutical and Guolong Pharmaceutical are tasked with serving as pilot entities to build themselves into the industry’s leading API manufacturer. They are expected to accelerate transformation across production, quality, management, and marketing; expedite the upgrading of intelligent information infrastructure; and leverage smart manufacturing to spearhead the Group’s high-quality development.

The new era inspires us to forge ahead, and the new blueprint fills us with hope. The conference calls on all employees to embrace a sense of urgency—“we cannot afford to wait”—a sense of crisis—“we cannot afford to lag behind”—and a sense of responsibility—“we cannot sit idly by.” We must consistently uphold the heroic spirit and vigorous fighting spirit of “the more arduous the challenges, the more we press forward,” consciously strive for world-class standards, proactively benchmark against leading practices, maintain high efficiency and a fast pace in our work at all times, and adopt a relentless, “every minute counts” mindset to ensure the timely completion of all goals and tasks, thereby welcoming the successful convening of the 20th National Congress of the Communist Party of China with outstanding achievements!

Keywords:

2022 New Year’s Greeting

Wang Jinshan, Secretary of the CPC Gaocheng District Committee, Conducts In-Depth Field Inspection at the Construction Site of the Guolong Pharmaceutical Project of Shisiyao Group

2022 New Year’s Greeting

Wang Jinshan, Secretary of the CPC Gaocheng District Committee, Conducts In-Depth Field Inspection at the Construction Site of the Guolong Pharmaceutical Project of Shisiyao Group